Overview
Xilio” (pronounced “ex-il-ee-oh”) is derived from the Latin term Ex Nihilo, meaning creation or big-bang, and embodies the company’s vision to create transformative treatments for individuals living with cancer by unleashing the full power of highly potent immune therapies selectively in tumors.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.
Xilio was founded in 2016 and is headquartered in Waltham, MA.